9个撒哈拉以南非洲国家改善儿童结核病诊断与预防治疗的干预措施成本效果分析:一项模型研究
该研究分析9个撒哈拉以南非洲国家146个诊所的前后数据,评估CaP-TB干预包对0至14岁儿童结核病诊断、抗结核治疗启动和结核病预防治疗覆盖的影响,并建模分析成本效果。结果显示抗结核治疗和预防治疗的启动率总体上升,但各国差异大,中位ICER为每避免一个伤残调整生命年634美元。
要点
- CaP-TB干预包在多数国家改善了15岁以下儿童的结核病治疗和预防服务。
- 各国抗结核治疗启动率比在0.8至2.9之间,预防治疗启动率比在1.6至9.8之间。
- 中位ICER为每避免一个DALY 634美元,各国从135至6804美元不等。
核心结论
- 在多数国家,CaP-TB干预包改善了15岁以下儿童的结核病治疗和预防服务,但估计影响和ICER的巨大差异凸显了当地背景的重要性。
研究设计与样本
- 对9个撒哈拉以南非洲国家146个诊所的干预前后数据进行分析,按0至4岁和5至14岁年龄组分层。
- 干预前数据从机构登记册回顾性收集12个月,干预数据于2018年12月至2021年6月使用项目专用表格前瞻性收集。
- 使用贝叶斯广义线性混合效应模型估计国家层面结核病诊断和抗结核治疗/预防治疗启动的率比,并分析项目支出和级联数据,结合数学建模预测健康影响、卫生系统成本和成本效果。
主要发现
- 国家层面抗结核治疗启动的发病率比在0.8(95%不确定性区间[UI] 0.7至1.0)至2.9(95% UI 2.3至3.6)之间。
- 国家层面结核病预防治疗启动的发病率比在1.6(95% UI 1.5至1.8)至9.8(95% UI 8.1至11.8)之间。
- 基线时每100名开始抗结核治疗或预防治疗的儿童,干预包可避免1例(95% UI -1至3)至38例(95% UI 24至58)死亡。
- 中位增量成本效果比(ICER)为每避免一个伤残调整生命年(DALY)634美元,各国从刚果民主共和国的135美元/DALY至喀麦隆的6804美元/DALY不等。
局限性
- 本研究的主要局限性是影响基于前后比较,可能存在混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over 1 million children aged 0 to 14 years were estimated to develop tuberculosis in 2021, resulting in over 200,000 deaths. Practical interventions are urgently needed to improve diagnosis and antituberculosis treatment (ATT) initiation in children aged 0 to 14 years and to increase coverage of tuberculosis preventive therapy (TPT) in children at high risk of developing tuberculosis disease. The multicountry CaP-TB intervention scaled up facility-based intensified case finding and strengthened household contact management and TPT provision at HIV clinics. To add to the limited health-economic evidence on interventions to improve ATT and TPT in children, we evaluated the cost-effectiveness of the CaP-TB intervention. METHODS AND FINDINGS: We analysed clinic-level pre/post data to quantify the impact of the CaP-TB intervention on ATT and TPT initiation across 9 sub-Saharan African countries. Data on tuberculosis diagnosis and ATT/TPT initiation counts with corresponding follow-up time were available for 146 sites across the 9 countries prior to and post project implementation, stratified by 0 to 4 and 5 to 14 year age-groups. Preintervention data were retrospectively collected from facility registers for a 12-month period, and intervention data were prospectively collected from December 2018 to June 2021 using project-specific forms. Bayesian generalised linear mixed-effects models were used to estimate country-level rate ratios for tuberculosis diagnosis and ATT/TPT initiation. We analysed project expenditure and cascade data to determine unit costs of intervention components and used mathematical modelling to project health impact, health system costs, and cost-effectiveness. Overall, ATT and TPT initiation increased, with country-level incidence rate ratios varying between 0.8 (95% uncertainty interval [UI], 0.7 to 1.0) and 2.9 (95% UI, 2.3 to 3.6) for ATT and between 1.6 (95% UI, 1.5 to 1.8) and 9.8 (95% UI, 8.1 to 11.8) for TPT. We projected that for every 100 children starting either ATT or TPT at baseline, the intervention package translated to between 1 (95% UI, -1 to 3) and 38 (95% UI, 24 to 58) deaths averted, with a median incremental cost-effectiveness ratio (ICER) of US$634 per disability-adjusted life year (DALY) averted. ICERs ranged between US$135/DALY averted in Democratic of the Congo and US$6,804/DALY averted in Cameroon. The main limitation of our study is that the impact is based on pre/post comparisons, which could be confounded. CONCLUSIONS: In most countries, the CaP-TB intervention package improved tuberculosis treatment and prevention services for children aged under 15 years, but large variation in estimated impact and ICERs highlights the importance of local context. TRIAL REGISTRATION: This evaluation is part of the TIPPI study, registered with ClinicalTrials.gov (NCT03948698).
引用
- Mafirakureva N, Mukherjee S, de Souza M, et al. Cost-effectiveness analysis of interventions to improve diagnosis and preventive therapy for paediatric tuberculosis in 9 sub-Saharan African countries: A modelling study. PLoS Med. 2023. PMID: 37672524. doi:10.1371/journal.pmed.1004285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。